<DOC>
	<DOCNO>NCT01189253</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin hydrochloride trabectedin , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether trabectedin effective doxorubicin hydrochloride treat patient advanced metastatic soft tissue sarcoma . PURPOSE : This randomized phase II/III trial study safety trabectedin compare doxorubicin hydrochloride see well work treat patient advanced metastatic soft tissue sarcoma .</brief_summary>
	<brief_title>Doxorubicin Hydrochloride Trabectedin Treating Patients With Previously Untreated Advanced Metastatic Soft Tissue Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate whether trabectedin give first-line chemotherapy patient previously untreated advanced metastatic malignant soft tissue sarcoma prolongs progression-free survival compare doxorubicin hydrochloride . - To identify validate biomarkers ( include , limited , XPG , BRCA1 , RAD51 , BRCA2 , ATM CHK1 ) sensitivity trabectedin order allow selection patient benefit trabectedin treatment . ( Optional translational research ) OUTLINE : This multicenter , phase IIB study follow phase III study . Patients stratify accord institution , age registration ( &lt; 60 year old v ≥ 60 year old ) , presence liver metastasis ( yes v ) . - Phase IIB ( step 1 ) : Patients randomize 1 3 treatment arm . - Arm I : Patients receive doxorubicin hydrochloride IV day 1 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . - Arm II : Patients receive trabectedin IV 3 hour day 1 . Courses repeat every 3 week absence disease progression unacceptable toxicity . - Arm III : Patients receive trabectedin IV continuously 24 hour day 1 . Courses repeat every 3 week absence disease progression unacceptable toxicity . At end step 1 , best regimen trabectedin determine . Patients receive non-selected trabectedin regimen ( `` lose arm '' ) offer cross order receive select regimen trabectedin . - Phase III ( step 2 ) : Patients randomize 1 2 treatment arm . - Arm I : Patients receive trabectedin IV day 1 use preferred regimen determine step 1 . Courses repeat every 3 week absence disease progression unacceptable toxicity . - Arm II : Patients receive doxorubicin hydrochloride IV day 1 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . Patients complete quality life questionnaire ( EORTC QLQ-C30 version 3 ) baseline , 6 , 12 , 24 , 36 week study , end study . Tumor tissue block obtain diagnosis may analyze identify validate biomarkers sensitivity trabectedin tissue microarrays . After completion study therapy , patient follow 1 month , every 6 12 week disease progression , every 12 week thereafter .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm intermediate highgrade malignant soft tissue sarcoma Advanced and/or metastatic disease Previously untreated disease The following tumor type allow : Welldifferentiated liposarcoma Embryonal rhabdomyosarcoma Chondrosarcoma ( exclude extraskeletal myxoid chondrosarcoma ) Osteosarcoma ( exclude extraskeletal osteosarcoma ) Ewing tumors/primitive neuroectodermal tumor ( PNET ) Gastrointestinal stromal tumor ( GIST ) Dermatofibrosarcoma protuberans Must confirm disease progression base investigator 's judgment prior study enrollment Measurable disease accord RECIST v 1.1 criterion Tumor lesion situate previously irradiate area , area subject locoregional therapy , usually consider measurable unless demonstrate progression lesion Formalin fix paraffin embed tumor block representative hematoxylin/eosin slide ( preferably ) available ( local histopathological diagnosis accept trial entry ) No prior anticancer therapy disease No prior anthracycline Nonanthracycline therapy nonmetastatic disease acceptable No known history CNS metastases leptomeningeal tumor spread PATIENT CHARACTERISTICS : WHO performance status 01 Absolute neutrophil count ≥ 1.5 x 10^9/L Hemoglobin ≥ 9 g/dL Platelet count ≥ 100 x 10^9/L Bilirubin normal ALT/AST ≤ 2.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN , ( alkaline phosphatase &gt; 2.5 time ULN , hepatic isoenzymes 5nucleotidase and/or GGT must within normal range ) Albumin &gt; 30 g/L Serum creatinine ≤ 1.5 time ULN Creatinine clearance ≥ 30 mL/min Creatine phosphokinase ( CPK ) ≤ 2.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ( double barrier method men ) 2 week prior , , 3 month ( woman ) 5 month ( men ) completion study therapy LVEF normal MUGA scan ECHO 12lead ECG normal ( without clinically significant abnormality ) None follow unstable cardiac condition : Congestive heart failure Angina pectoris Myocardial infarction within past year Uncontrolled arterial hypertension , define BP ≥ 150/100 mm Hg despite optimal medical therapy Clinically significant arrhythmias No active uncontrolled infection serious illness medical condition , include history following : Chronic alcohol abuse Hepatitis HIV Cirrhosis No history malignancy within past 5 year , except soft tissue sarcoma , basal cell squamous cell carcinoma skin , carcinoma situ cervix , resect incidental prostate cancer ( stag pT2 Gleason score ≤ 6 postoperative PSA &lt; 0.5 ng/mL ) Patients history malignancy diseasefree 5 year eligible history malignancy diseasefree 5 year No psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule No concurrent alcohol consumption PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 28 day since prior concurrent anticancer therapy include systemic therapy , radiotherapy , surgery At least 28 day since prior concurrent investigational agent No concurrent phenytoin , live attenuate vaccine , yellow fever vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
	<keyword>adult alveolar soft-part sarcoma</keyword>
	<keyword>adult angiosarcoma</keyword>
	<keyword>adult desmoplastic small round cell tumor</keyword>
	<keyword>adult epithelioid sarcoma</keyword>
	<keyword>adult extraskeletal chondrosarcoma</keyword>
	<keyword>adult extraskeletal osteosarcoma</keyword>
	<keyword>adult fibrosarcoma</keyword>
	<keyword>adult leiomyosarcoma</keyword>
	<keyword>adult malignant fibrous histiocytoma</keyword>
	<keyword>adult malignant hemangiopericytoma</keyword>
	<keyword>adult malignant mesenchymoma</keyword>
	<keyword>adult neurofibrosarcoma</keyword>
	<keyword>adult synovial sarcoma</keyword>
</DOC>